VIDEO: UBX1325 in wet AMD does not meet noninferiority endpoint despite good results
Click Here to Manage Email Alerts
Key takeaways:
- UBX1325 did not achieve noninferiority to aflibercept despite good 6-month results.
- UBX1325 maintained visual acuity and was well tolerated.
In this Healio Video Perspective from the Vit-Buckle Society meeting, Michael A. Singer, MD, discusses the results of the phase 2 ENVISION trial investigating UBX1325 for the treatment of wet age-related macular degeneration.
According to Singer, UBX1325 did not achieve noninferiority to aflibercept despite showing stable vision due to an initial bump in visual acuity in patients treated with aflibercept.
“The UBX study was well tolerated. [Patients] had no intraocular inflammation. [UBX1325] maintained visual acuity through 24 weeks in patients with active disease ... 52% of the patients were allowed to avoid anti-VEGF treatment for at least 6 months, and we think it probably would have a greater effect in more chronic patients or patients who have a diagnosis of at least 2 years,” he said.
Collapse
Singer MA, et al. First time clinical trial data: ENVISION trial 24-week data, phase 2 study of UBX1325, a novel
senolytic agent for patients with wet AMD. Presented at: Vit-Buckle Society meeting; April 13-15, 2023; Las Vegas.
Read more about
Click Here to Manage Email Alerts